Apellis Pharmaceuticals Stock (NASDAQ: APLS) stock price, news, charts, stock research, profile.
Open | $48.840 |
Close | $49.930 |
Volume / Avg. | 1.246M / 1.346M |
Day Range | 48.624 - 50.405 |
52 Wk Range | 19.830 - 94.750 |
Market Cap | $5.809B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 33 |
Short Interest | 10.05% |
Days to Cover | 9.5 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Apellis Pharmaceuticals (NASDAQ: APLS) through any online brokerage.
Other companies in Apellis Pharmaceuticals’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Ionis Pharmaceuticals (NASDAQ:IONS) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Apellis Pharmaceuticals (NASDAQ: APLS) was reported by Wedbush on Wednesday, April 17, 2024. The analyst firm set a price target for 57.00 expecting APLS to rise to within 12 months (a possible 18.33% upside). 69 analyst firms have reported ratings in the last year.
The stock price for Apellis Pharmaceuticals (NASDAQ: APLS) is $48.1716 last updated April 24, 2024 at 4:33 PM EDT.
There are no upcoming dividends for Apellis Pharmaceuticals.
Apellis Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Apellis Pharmaceuticals.
Apellis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.